Last reviewed · How we verify
Osmotic-release oral system methylphenidate
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Osmotic-release oral system methylphenidate |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Central nervous system stimulant |
| Target | Dopamine transporter (DAT), Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters (DAT and NET), leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The osmotic-release oral system (OROS) formulation provides controlled, extended-release delivery over approximately 12 hours.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Abdominal pain
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original (NA)
- A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder (PHASE2)
- A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
- A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants (PHASE4)
- The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) (PHASE4)
- An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) (PHASE4)
- Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: